Randomized, prospective, double-blind study to objectively demonstrate the performance and safety of the Rayocomp bioresonance device in patients with cervical spine disorder
Organizational Data
- DRKS-ID:
- DRKS00017381
- Recruitment Status:
- Recruiting complete, study complete
- Date of registration in DRKS:
- 2019-05-22
- Last update in DRKS:
- 2020-05-14
- Registration type:
- Prospective
Acronym/abbreviation of the study
R-HWS
URL of the study
No Entry
Brief summary in lay language
The study will assess the pain relief and improvement in the quality of life of patients with cervical spine disorder who have been treated with the Rayocomp bioresonance device. The study participants fill in questionnaires on quality of life, performance and neck pain (NDI). The study also assesses demographic and medical history data. In addition, the safety of the treatment will be investigated by recording adverse events during the study. During the study phase, 10 sessions of therapy with the Rayocomp bioresonance device or with a non-functional device (placebo) take place within up to 21 days. The evaluation of the data collected in this study is intended to increase knowledge of bioresonance therapy and to improve the treatment of patients with cervical spine disorder.
Brief summary in scientific language
This study is a randomized, prospective, double-blind study according to MPG §23b investigating treatment with the Rayocomp bioresonance device. The Rayocomp bioresonance device is a CE-certified medical device for alleviating the pain symptoms in patients with cervical spine disorder. The primary objective of the study is effectiveness as measured by the NDI; secondary objectives are safety, quality of life and VAS. A total of 52 patients shall be enrolled.
Health condition or problem studied
- ICD10:
- M54 - Dorsalgia
- ICD10:
- M53 - Other dorsopathies, not elsewhere classified
- Healthy volunteers:
- No Entry
Interventions, Observational Groups
- Arm 1:
- Treatment with the Rayocomp Bioresonance Device, 10 treatments over 21 days with acquisition of AE, demography, med. history at BL, determination of VAS, pain medication, 3 questionnaires - quality of life, performance, NID at BL and after last treatment, subjective assessment of therapeutic success after last treatment
- Arm 2:
- Treatment with non-functional Rayocomp Bioresonance Device (placebo), 10 treatments over 21 days with acquisition of AE, demography, med. history at BL, determination of VAS, pain medication, 3 questionnaires - quality of life, performance, NID at BL and after last treatment, subjective assessment of therapeutic success after last treatment
Endpoints
- Primary outcome:
- Neck pain, as measured by the Neck Disability Index (NDI), before and after treatment with the Rayocomp bioresonance device compared to placebo
- Secondary outcome:
- Safety, as measured by the incidence of adverse events Quality of life measured on the SF-36 before and after treatment with the Rayocomp bioresonance device compared to the placebo VAS before and after treatment with the Rayocomp bioresonance device compared to placebo
Study Design
- Purpose:
- Treatment
- Allocation:
- Randomized controlled study
- Control:
-
- Placebo
- Phase:
- IV
- Study type:
- Interventional
- Mechanism of allocation concealment:
- No Entry
- Blinding:
- Yes
- Assignment:
- Parallel
- Sequence generation:
- No Entry
- Who is blinded:
-
- Investigator/therapist
- Patient/subject
Recruitment
- Recruitment Status:
- Recruiting complete, study complete
- Reason if recruiting stopped or withdrawn:
- No Entry
Recruitment Locations
- Recruitment countries:
-
- Germany
- Number of study centers:
- Monocenter study
- Recruitment location(s):
-
- Doctor's practice Melbeck
Recruitment period and number of participants
- Planned study start date:
- 2019-05-23
- Actual study start date:
- 2019-05-25
- Planned study completion date:
- No Entry
- Actual Study Completion Date:
- 2019-12-12
- Target Sample Size:
- 52
- Final Sample Size:
- 54
Inclusion Criteria
- Sex:
- All
- Minimum Age:
- 18 Years
- Maximum Age:
- no maximum age
- Additional Inclusion Criteria:
- 1) Gender: male and female 2) Age: at least 18 years 3) At least moderate pain (≥ 5 on the VAS) in the cervical spine area 4) Neck disabilty index with at least medium restriction (score ≥ 15) 5) Patients must be able to understand the patient information 6) Patients must be willing and able to meet the requirements of the study 7) Signed ICF
Exclusion Criteria
1) Systemic or inflammatory musculoskeletal disease (e.g., muscular dystrophies, polymyositis) 2) Trauma with fractures and surgical treatment 3) Severe systemic disease with a life expectancy <6 months (e.g., advanced heart failure, malignancies) 4) Massive degenerative disease with marked restriction of motility (e.g., polyarthritis) 5) Pregnant or breastfeeding female patients without effective contraception 6) Patients who, due to mental illness, are unable to understand the study information, give their consent, or adhere to the study's guidelines 7) Patients who, in the opinion of the investigator, are not suitable for the study 8) Alcohol or drug abuse 9) patients incapable of giving consent 10) Persons who are in a dependency or employment relationship with the sponsor or investigator 11) Detained persons 12) Participation in another study
Addresses
Primary Sponsor
- Address:
- Rayonex Biomedical GmbHSauerland-Pyramiden 157368 LennestadtGermany
- Telephone:
- +49 (0) 2721 6006-0
- Fax:
- +49 (0) 2721 6006-67
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.rayonex.de
- Investigator Sponsored/Initiated Trial (IST/IIT):
- No
Contact for Scientific Queries
- Address:
- Praxis Dr.med. Axel SchußmannDr. med. Axel SchußmannZur Ohe 221406 MelbeckGermany
- Telephone:
- +49 (0) 4134 900313
- Fax:
- +49 (0) 4134 900483
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Contact for Public Queries
- Address:
- Praxis Dr.med. Axel SchußmannDr. med. Axel SchußmannZur Ohe 221406 MelbeckGermany
- Telephone:
- +49 (0) 4134 900313
- Fax:
- +49 (0) 4134 900483
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Principal Investigator
- Address:
- Praxis Dr.med. Axel SchußmannDr. med. Axel SchußmannZur Ohe 221406 MelbeckGermany
- Telephone:
- +49 (0) 4134 900313
- Fax:
- +49 (0) 4134 900483
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Sources of Monetary or Material Support
Commercial (pharmaceutical industry, medical engineering industry, etc.)
- Address:
- Rayonex Biomedical GmbHSauerland-Pyramiden 157368 LennestadtGermany
- Telephone:
- +49 (0) 2721 6006-0
- Fax:
- +49 (0) 2721 6006-67
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- http://www.rayonex.de
Ethics Committee
Address Ethics Committee
- Address:
- Ethikkommission bei der Ärztekammer Niedersachsen, Unterkommission zur Beurteilung medizinischer Forschung am MenschenKarl-Wiechert-Allee 18-2230625 HannoverGermany
- Telephone:
- +49-511-3802208
- Fax:
- +49-511-3802119
- Contact per E-Mail:
- Contact per E-Mail
- URL:
- No Entry
Vote of leading Ethics Committee
- Vote of leading Ethics Committee
- Date of ethics committee application:
- 2019-02-26
- Ethics committee number:
- 11/2019
- Vote of the Ethics Committee:
- Approved
- Date of the vote:
- 2019-02-28
Further identification numbers
- Other primary registry ID:
- No Entry
- EudraCT Number:
- No Entry
IPD - Individual Participant Data
- Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
- No
- IPD Sharing Plan:
- No Entry
Study protocol and other study documents
- Study protocols:
- No Entry
- Study abstract:
- No Entry
- Other study documents:
- No Entry
- Background literature:
- No Entry
- Related DRKS studies:
- No Entry
Publication of study results
- Planned publication:
- No Entry
- Publikationen/Studienergebnisse:
- R-HWS Zusammenfassung der Ergebnisse
- Date of first publication of study results:
- No Entry
- DRKS entry published for the first time with results:
- No Entry
Basic reporting
- Basic Reporting / Results tables:
- No Entry
- Brief summary of results:
- No Entry